A total of 396 patients with moderate-to-severe psychotic symptoms were randomized to receive either pimavanserin or placebo added to their current antipsychotic treatment. There is currently no FDA-approved
The post ACADIA announces top-line results from phase 3 schizophrenia trial of Pimavanserin appeared first on Pharmaceutical Business review.